---
title: "Sagimet Biosciences Jumps 41% After Securing $175M for Phase 3 Acne Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284242135.md"
description: "Sagimet Biosciences（SGMT.US）现价 $8.282，当日 +41.33%，盘中大幅拉升，触及阶段性高位。生物医药公司 Sagimet Biosciences 今日公告获得 1.75 亿美元融资，用于在美国推进其痤疮药物的三期临床试验，此举直接催化股价跳升。资金到位意味着该管线项目的临床推进障碍大幅降低，市场重新评估其研发进展的确定性溢价。公司同时披露了其他管线进展，进一步强化了投资者对整体研发布局的信心。"
datetime: "2026-04-27T15:21:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284242135.md)
  - [en](https://longbridge.com/en/news/284242135.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284242135.md)
---

# Sagimet Biosciences Jumps 41% After Securing $175M for Phase 3 Acne Trial

Sagimet Biosciences (SGMT.US) traded at $8.282, up **+41.33%** intraday, reaching a notable intraday high on significantly elevated volume.

The clinical-stage biopharmaceutical company announced $175 million in funding to advance its Phase 3 acne treatment trial in the United States, removing a key financing overhang and directly triggering the sharp price move. The secured capital materially de-risks the trial timeline and leads the market to reprice the probability-weighted value of its lead pipeline asset. Sagimet also highlighted broader pipeline progress and strategic corporate developments alongside the funding announcement, reinforcing investor confidence in the company's clinical roadmap.

### Related Stocks

- [SGMT.US](https://longbridge.com/en/quote/SGMT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative](https://longbridge.com/en/news/287245995.md)
- [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)